Stay updated on TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.

Latest updates to the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.8%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check75 days agoChange DetectedThe page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the name of a collaborator, Trillium Therapeutics Inc., while removing detailed descriptions of the study's objectives and inclusion/exclusion criteria for participants with multiple myeloma.SummaryDifference42%
Stay in the know with updates to TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.